# Why The Critique Said The Premise Was False

## Summary

The research step did not conclude that the SpaceX/SPCX premise was false.

The research step concluded that the thesis was partially supported: the SEC filing and financial figures were supported, while the valuation multiple was only conditionally supported because the $1.75 trillion valuation was not stated in the S-1.

The false-premise language came from the critique step. That critique contradicted the completed research report and introduced stale or unsupported facts.

## What Research Found

The research report supported the core factual setup:

```text
SEC S-1 exists
accession number matches the cited filing
2025 revenue was about $18.7B
2025 operating loss was about $2.6B
Q1 2026 revenue was about $4.7B
Q1 2026 operating loss was about $1.9B
SPCX was treated as the intended SpaceX ticker
```

The main caveat was valuation.

The S-1 did not itself establish a $1.75 trillion valuation. Research treated the 93x sales math as conditional on an external banker or media valuation target.

So the accurate research stance was:

```text
partially supported
plausible but unconfirmed
proceed with caution
```

## What Critique Got Wrong

The critique step said the premise was false because it claimed:

```text
SpaceX had not filed an S-1
SpaceX was still only private
SPCX was an unrelated ETF ticker
the $1.75T valuation was a hallucinated 10x error
```

Those claims contradicted the research report that had already resolved the filing, ticker, and financial figures.

This means the critique did not stay grounded in the supplied research evidence. It appears to have fallen back to stale prior knowledge, where SpaceX was private and SPCX may have referred to another instrument, instead of respecting the current run's resolved evidence.

## Root Cause

This is a critique grounding bug.

The model running `critique_thesis` was allowed to introduce new factual objections without proving that those objections came from the research report. Because of that, it produced a confident objection that contradicted the evidence ledger and goal resolutions.

The problem was not the research result.

The problem was this handoff:

```text
ResearchReport says: partially supported, valuation conditional
Critique says: premise entirely false
Final response follows critique tone
```

## Correct Interpretation

The right final interpretation should have been:

```text
The post is directionally fair on the S-1 financials.
The cited revenue and operating-loss figures are supported.
The bearish framing is reasonable as a valuation critique.
The weak link is the $1.75T valuation, because it is not directly disclosed in the S-1.
Therefore the 93x sales claim should be framed as conditional, not as fully established by the filing.
```

## Product Fix

The critique step should be constrained so it cannot contradict resolved research unless it cites stronger evidence from the same report.

Recommended guardrails:

```text
Critique objections must cite evidence IDs or goal resolution IDs.
Critique cannot contradict resolved_supported goals without naming specific contrary evidence.
Critique should distinguish "unsupported by filing" from "false".
Finalization should run a consistency check between research stance and critique stance.
If critique says "false premise" while research says "partially supported", finalization should downgrade or reject the critique.
```

## Expected Behavior

For this run, critique should have focused on the real weakness:

```text
The S-1 supports the operating figures, but the $1.75T valuation is not disclosed in the S-1.
The 93x sales multiple is only valid if that external valuation target is accepted.
That makes the thesis usable as a criticism, but not fully proven by the filing alone.
```
